Telix Pharmaceuticals Cash Flow Statement
NASDAQ: TLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Telix Pharmaceuticals free cash flow
In fiscal 2025, Telix Pharmaceuticals generated -$17.3 million of operating cash flow and spent $25.7 million on capital expenditures. That left free cash flow of -$43.0 million, a free-cash-flow margin of -5.3% of revenue. Free cash flow was down 334.0% from the prior year's $18.4 million.
Summary generated from market data by MetaCap's automated system. Methodology
Telix Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | -7.13M | 33.69M | 4.21M |
| Net Income growth (YoY) | -121.15% | +700.50% | — |
| Depreciation & Amortization | 21.41M | 5.28M | 4.16M |
| Stock-Based Compensation | 19.35M | 12.93M | 5.85M |
| Operating Cash Flow | -17.29M | 27.49M | 14.27M |
| Capital Expenditures | -25.69M | -9.12M | -6.31M |
| Investing Cash Flow | -285.92M | -86.69M | -16.84M |
| Debt Issued | 529.00K | 427.90M | 4.19M |
| Debt Repaid | -819.00K | -745.00K | 0 |
| Financing Cash Flow | -3.72M | 416.79M | 7.09M |
| Free Cash Flow | -42.98M | 18.37M | 7.97M |
This table shows 3 annual periods of Telix Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TLX's reporting calendar. What is a cash flow statement?